Innovotech Inc. Receives Funding for Antimicrobial Testing Development

Edmonton, Alberta — May 13, 2026 — Leads & Copy — Innovotech Inc. is receiving up to $234,000 CAD in advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop new antimicrobial testing services.

The funding will support the development of testing services for use with medical devices such as catheters, implants, and wound dressings, according to the company.

Innovotech Labs Corporation, a subsidiary of Innovotech, will receive the funding.

The new testing methods align with changes in international regulatory standards and the needs of medical device manufacturers regarding proliferation, biofilm formation, and translocation of microorganisms, the company said.

The work builds on foundational development that began last year and advances it into more robust, fit-for-purpose testing. According to the company, customer programs are expanding, and manufacturers are requesting more advanced testing that better reflects real-world use and provides clearer decision-making data.

Strengthening these capabilities will expand the company's service offerings, support regulatory readiness, and help customers demonstrate device safety and performance more effectively.

Craig Milne, CEO, said that the NRC IRAP support will help Innovotech deepen its technical bench, problem solve for its customers, and deliver solutions that reduce infections and complications for better health outcomes. He added that it also positions the company to meet rising client demand with higher-complexity testing and stronger technical support as standards and expectations continue to evolve.

Innovotech Inc. specializes in contract research, analytical, and microbial testing within regulated healthcare markets. The company is a recognized leader in biofilm science and antimicrobial testing and provides advanced laboratory services supporting medical device, pharmaceutical, and industrial product development.

The company combines scientific expertise with proprietary methodologies and products, including its MBEC Assay platform for high‑throughput antimicrobial and antibiotic testing. Innovotech operates through ISO‑certified and GMP‑accredited laboratories, supporting clients across multiple sectors and geographies, delivering reliable, decision‑enabling data aligned with regulatory expectations such as those of the U.S. Food and Drug Administration and Health Canada.

Source: Innovotech Inc.